Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02478177 · ClinicalTrials.gov registry record

Addressing Real-world Anticoagulant Management Issues in Stroke

A clinical trial of Stroke and Intracerebral Hemorrhage, sponsored by Duke University.

Completed
Registry status
6,000
Enrollment target
1
Study location

NCT02478177 is a study of Stroke and Intracerebral Hemorrhage that has completed, run by Duke University. The registered enrollment target is 6,000 participants, below the 12,003-participant average among 454 other Stroke trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02478177, a study of Stroke and Intracerebral Hemorrhage, has completed, sponsored by Duke University.

COMPLETED
Registry status
6,000 participants
Enrollment target
1
Study location

Study Summary

The Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) registry is designed to provide important and timely insight into the management of acute stroke patients who are on novel oral anticoagulants in community practice.

Study Locations (1)

North Carolina

  • 300 West Morgan Street, Duke Clinical Research Institute - Durham

Trial Details

FieldValue
Enrollment Target 6,000 participants
Start Date 2015-09
Est. Completion 2019-12

Sponsor

Duke University

1,725 total trials

What the Registry Record Tells You About NCT02478177

The ClinicalTrials.gov registry entry for NCT02478177 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 6,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,003-participant average among 454 other Stroke trials with a reported enrollment target (50% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Stroke appearing as the primary indexed condition, and to 0 interventions.

NCT02478177 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT02478177 about?

NCT02478177 is a clinical study titled "Addressing Real-world Anticoagulant Management Issues in Stroke". The Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) registry is designed to provide important and timely insight into the management of acute stroke patients who are on novel oral anticoagulants in community practice.

What is the current status of trial NCT02478177?

This trial is currently completed. The enrollment target is 6,000 participants. The study started on 2015-09. Estimated completion is 2019-12.

What conditions does trial NCT02478177 study?

This clinical trial studies the following conditions: Stroke, Intracerebral Hemorrhage, Cerebrovascular Stroke.

Who is sponsoring clinical trial NCT02478177?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02478177 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.